MetLife (MET)
(Delayed Data from NYSE)
$70.42 USD
-1.48 (-2.06%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MET 70.42 -1.48(-2.06%)
Will MET be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MET based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MET
MetLife (MET) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
MetLife (MET) Earnings Expected to Grow: Should You Buy?
MET: What are Zacks experts saying now?
Zacks Private Portfolio Services
MetLife (MET) Launches Savings Calculator to Educate Pet Parents
5 Dividend-Paying Multiline Insurers Worth Watching
MetLife's (MET) Connected Benefits to Enhance Employer Offerings
Other News for MET
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more
Wall Street Breakfast: The Week Ahead
Dividend Champion, Contender, And Challenger Highlights: Week Of April 28
Dividend Roundup: MetLife, General Motors, Pfizer, Citigroup, and more